Abstract
Replication-competent adenoviruses (Ad's) are emerging as a promising new modality for treatment of cancer. Selective replication of viral agents in tumor may lead to improved efficacy over nonreplicating Ad's due to their inherent ability to multiply, lyse, and spread to surrounding cells. We have previously shown that an E1B 55 kDa-deleted adenovirus (YKL-1) exhibits tumor-specific replication and cell lysis, but its cytolytic effects were reduced in comparison to the wild-type adenovirus. To increase the oncolytic potency of YKL-1, we have reintroduced the Ad death protein (ADP) gene under the control of either a CMV or an MLP promoter at the E3 region of YKL-1, generating YKL-cADP and YKL-mADP Ad's, respectively. ADP is an 11.6 kDa protein encoded by the E3 transcription unit, and is required to kill adenovirus-infected cells efficiently. However, to date, the mechanism by which ADP mediates cell death has not been clearly defined. In this study, we report that ADP-overexpressing Ad markedly enhanced cytolytic effect (up to 100-fold) against all tumor cell lines tested, but did not increase cytopathic effect in normal skin fibroblast, BJ. Moreover, plaque size formed by YKL-cADP was substantially larger than that of YKL-1, indicating an enhancement in cell lysis. TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay and Annexin-V/PI double staining indicate that ADP-mediated cytotoxicity was largely driven by apoptosis. Finally, YKL-cADP adenovirus also showed superior antitumor effect than YKL-1 and YKL-mADP in C33A cervical and Hep3B hepatoma xenograft tumor models. Taken together, these lines of evidence demonstrate that the newly generated adenovirus expressing ADP under the CMV promoter induces efficient but tumor-selective cell lysis, which is critical for adding therapeutic value to replicating adenovirus for its use in cancer gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kirn D . Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene. 2000; 19: 6660–6669.
Kirn D . Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther. 2001; 1: 525–538.
Kirn D . Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy. 2001; 8: 89–98.
Lee H, Kim J, Lee B, et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer. 2000; 88: 454–463.
Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kDa gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000; 60: 6359–6366.
Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000; 6: 798–806.
Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000; 18: 609–622.
Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6: 879–885.
Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM . A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol. 2000; 7: 588–592.
Yang Y, Li Q, Ertl HC, Wilson JM . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995; 69: 2004–2015.
Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM . Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA. 1995; 92: 1401–1405.
Wold WS, Tollefson AE, Hermiston TW . E3 transcription unit of adenovirus. Curr Top Microbiol Immunol. 1995; 199(Part 1): 237–274.
Paabo S, Bhat BM, Wold WS, Peterson PA . A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell. 1987; 50: 311–317.
Burgert HG, Kvist S . An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 1985; 41: 987–997.
Shisler J, Yang C, Walter B, Ware CF, Gooding LR . The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol. 1997; 71: 8299–8306.
Zanardi TA, Yei S, Lichtenstein DL, Tollefson AE, Wold WS . Distinct domains in the adenovirus E3 RIDalpha protein are required for degradation of Fas and the epidermal growth factor receptor. J Virol. 2003; 77: 11685–11696.
Tollefson AE, Hermiston TW, Lichtenstein DL, et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 1998; 392: 726–730.
Krajcsi P, Dimitrov T, Hermiston TW, et al. The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J Virol. 1996; 70: 4904–4913.
Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WS . A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell. 1988; 53: 341–346.
Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE . Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999; 11: 380–386.
Horwitz MS . Adenovirus immunoregulatory genes and their cellular targets. Virology. 2001; 279: 1–8.
Mahr JA, Gooding LR . Immune evasion by adenoviruses. Immunol Rev. 1999; 168: 121–130.
Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS . The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol. 1996; 70: 2296–2306.
Tollefson AE, Scaria A, Saha SK, Wold WS . The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol. 1992; 66: 3633–3642.
Kim J, Cho JY, Kim JH, Jung KC, Yun CO . Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 2002; 9: 725–736.
Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M . Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996; 70: 4805–4810.
Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995; 182: 1545–1556.
Wold WS, Cladaras C, Magie SC, Yacoub N . Mapping a new gene that encodes an 11,600-molecular-weight protein in the E3 transcription unit of adenovirus 2. J Virol. 1984; 52: 307–313.
Scaria A, Tollefson AE, Saha SK, Wold WS . The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane. Virology. 1992; 191: 743–753.
Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS . The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology. 1996; 220: 152–162.
Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS . Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000; 74: 6147–6155.
Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol. 2001; 75: 3314–3324.
Habib NA, Mitry R, Seth P, et al. Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 2002; 9: 651–654.
Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. 2001; 19: 1035–1041.
Acknowledgements
We thank all of our colleagues at Yonsei Cancer Center, Seoul, Korea, who have contributed to these studies. This work was supported by grants from the Ministry of Commerce Industry and Energy, Republic of Korea (990-14-05-00008131, Dr. C-O Yun) and the Korea Food and Drug Administration, Republic of Korea (KFDA-03132-GEN-080-5, Dr. C-O Yun). Eunhee Kim, Young-sook Lee, and Taeyoung Koo are graduate students sponsored by the Brain Korea 21 Project for Medical Science, Yonsei University, Seoul, South Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yun, CO., Kim, E., Koo, T. et al. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 12, 61–71 (2005). https://doi.org/10.1038/sj.cgt.7700769
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700769
Keywords
This article is cited by
-
Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer
Gene Therapy (2014)
-
Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy
Gene Therapy (2013)
-
Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF
Gene Therapy (2012)
-
Adenovirus i-Leader Truncation Bioselected Against Cancer-associated Fibroblasts to Overcome Tumor Stromal Barriers
Molecular Therapy (2012)
-
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα
Gene Therapy (2011)